Oxxon launches operation in US

Published: 13-Apr-2004

UK biotech company Oxxon Therapeutics (formerly Oxxon Pharmaccines) has opened a new US operation based in Boston, Massachusetts.


UK biotech company Oxxon Therapeutics (formerly Oxxon Pharmaccines) has opened a new US operation based in Boston, Massachusetts.

The company says the new operation puts it much closer to important medical and commercial opportunities and will assist it in pursuing its clinical programmes aggressively.

The new facility will initially employ four staff, building to a team of 10 over the next three years. Current activities including all laboratory-based research and early stage development and administration will continue to be run from the company's base in Oxford, UK.

To coincide with this move and for clarity, the company has changed its name to Oxxon Therapeutics. It focuses on developing immunotherapeutics for cancer and chronic infectious diseases based on its novel proprietary PrimeBoost technology.

'We will benefit from working with US clinicians as we enter the clinical phase of our development programmes for more of our drugs,' said Oxxon's ceo Dr Deirdre Gillespie. 'There are also many business development opportunities, which will positively impact upon both offices.'

Recently Wyeth's Dr Frank Malinoski was appointed chief medical officer, and Dr John Brown, formerly ceo of Acambis, joined the board.

  

You may also like